The hospitals and clinics segment to dominate by 2028

By -

The global cancer diagnostics market was estimated at $168.60 billion in 2020, and is estimated to reach $280.59 billion by 2028, growing at a CAGR of 6.9% from 2021 to 2028.

Rise in incidences and prevalence of various cancer types, initiatives by government and other organizations to spread awareness about cancer, and growth in number of diagnostics laboratories in developed countries propel the growth of the global cancer diagnostics market. On the other hand, risk of high radiation exposure by the use of CT scanners and high cost of diagnostics imaging systems hamper the market growth. Conversely, development of diagnostic approaches for various cancer mutations is expected to present opportunities for the industry in the future.

Covid-19 scenario:

  • The Covid-19 pandemic and followed lockdown delayed the diagnosis of cancer for a long period as it affected the logistics and supply of cancer diagnosis tests kits and other products.
  • Moreover, the limited availability of medical care and healthcare professionals for conditions other than Covid-19 negatively affected the market.
  • Several hospitals and clinics witnessed a drop in patient visits during the pandemic. The global cancer diagnostics market is segmented on the basis of product, application, end use, and region. Based on product, the consumables segment held the largest share in 2020, accounting for nearly three-fifths of the market. However, the instruments segment is estimated to portray the highest CAGR of 7.5% during the forecast period.

The hospitals and clinics segment to dominate by 2028-

Based on end use, the hospitals and clinics segment held the highest market share in 2020, with more than two-fifths of the market. This is due to higher flow of patients in the premises. However, the diagnostic laboratories segment is projected to register the highest CAGR of 7.8% from 2021 to 2028. This is attributed to growth in the technological advancements aiding in efficiency in obtaining images of the targeted area.

The North America region to rule the roost by 2028-

Based on region, the market across North America held the lion’s share in 2020, with more than two-fifths of the market. This is attributed to increase in number of patients suffering from cancer and growth in geriatric population in the region. However, the market across Asia-Pacific is expected to exhibit the highest CAGR of 8.5% during the forecast period. This is attributed to rise in focus of the key players on developing technologically advanced, cost-effective, and advanced safe products and high prevalence of cancer in the region.

Key market players-

  • Becton, Dickinson and Company
  • Abbott Laboratories
  • Roche Holdings AG (F. Hoffmann-La Roche Ltd.)
  • Bio-Rad Laboratories, Inc.
  • Hologic, Inc.
  • Danaher Corporation (GE Healthcare)
  • Qiagen N.V.
  • Koninklijke Philips N.V. (Philips Healthcare)
  • Thermo Fisher Scientific.
  • Siemens Healthcare GmbH.

Click Here @ 

https://www.globenewswire.com/en/news-release/2021/06/07/2242882/0/en/Cancer-Diagnostics-Market-Size-to-Reach-280-59-Billion-by-2028-Allied-Market-Research.html

Comments

Post a Comment

Popular posts from this blog

Global Cancer pain market is segmented based on drug type, disease indication, and region.

By -
According to a new report published by Allied Market Research, titled, "Cancer Pain Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"  the global cancer pain market was valued at $5,285 million in 2017, and is expected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025. Download the Sample Report @  https://www.alliedmarketresearch.com/request-sample/5123?utm_source=Blogger&utm_medium=Niranjan Cancer pain is chronic in nature and is commonly associated with cancer. It results from tissue damage, either due to the disease itself or due to different treatments such as chemotherapy, radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant market growth during the forecast period due to growth in demand for the drugs, surge in prevalence of cancer across the globe, increase in number of R&D activities to develop ideal cancer pain medications, and rise in the unmet nee...
Read more

U.S. was the largest country market in 2015, and is projected to maintain its lead until 2022.

By -
Image
  Surge in usage of wireless monitoring devices and increase in population of aging people across the globe drive the growth of the global patient monitoring devices market. However, high cost associated with patient monitoring devices is anticipated to restrain the market growth. Furthermore, increasing technological advancements are expected to provide new opportunities during the forecast period. The  Patient Monitoring Devices Market  generated $25.76 billion in 2019, and is estimated to reach $44.86 billion by 2027, registering a CAGR of 4.4% from 2020 to 2027. Based on product type, the cardiac monitoring devices segment contributed to the largest share in 2019, accounting for more than one-fourth of the total share, and is estimated to maintain its dominant position during the forecast period. However, the remote patient monitoring devices segment is estimated to portray the highest CAGR of 6.3% during the forecast period. Based on end-user, the hospitals segment a...
Read more